Our laboratory is focused on developing novel tools for quantitative optical molecular imaging within living subjects. The main focus of our current work is on advancing theoretical and experimental methods for whole-body time resolved imaging and fluorescence lifetime imaging. Although the ultimate goal of this research is clinical translation, the more immediate goal is geared towards pre-clinical applications, including high throughput and cost-effective drug discovery in small animal models. We are applying this technology to study preclinical models of cancer, cardiac disease, stroke and Alzheimer’s disease. We are also working with biochemists to further understand the photo-physical mechanisms underlying spectral and lifetime changes in "smart" or "activatable" molecular probes. The ultimate goal of these efforts is to optimize compounds that rapidly shift their optical spectra and fluorescence lifetimes upon binding to disease. The tools developed in our laboratory will ultmately enable biologists and pharmaceutical scientists better understand disease mechanisms and evaluate therapy response in meaningful physiological environments. We are also involved in a NIH-funded Academic Industry Partnership with PerkinElmer to commercialize a next generation preclinical time domain fluorescence imaging platform.

Article from the Martinos Center newsletter related to our recent paper in Cancer Research:  Development of cancer therapeutics could benefit from new fluorescence imaging technique

Research Fellow Position:

http://www.nmr.mgh.harvard.edu/omi/assets/ResearchFellowOpening_Martinos.pdf